Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tipifarnib + Osimertinib in EGFR-mutated NSCLC
NCT05693090Phase 1Withdrawn
- Sponsor
- Kura Oncology
- Start
- Feb 2023
- Primary completion
- Jul 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of tipifarnib in non-small cell lung cancer (NSCLC) (2 cohorts), sponsored by Kura Oncology. Primary endpoints: Recommended Phase 2 Dose at 28 days, Dose Limiting Toxicities at 1.5 years and 2 more. Planned start Feb 2023; status: withdrawn.
02
Drugs
tipifarnib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05693090.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05693090.